Posts by: Charles Moore

Charles Moore

Charles Moore has a long-proven track record in both print and digital journalism, touching on a wide range of subjects, from biotech and healthcare to politics and technology. He contributes substantial feature articles about RA research and development for the news site.

August 19, 2016August 19, 2016

Johnson & Johnson to Appeal Court Ruling That Favors Biosimilar Competition

News

In a press release, Johnson & Johnson announced recently that a District of Massachusetts Federal Court has ruled on a summary judgment motion filed by Celltrion Healthcare and Hospira Healthcare Corporation in patent ... Read more

August 12, 2016August 12, 2016

Lower-Cost Biosimilar Therapy Gets Unanimous FDA Panel Support

News

The US Food and Drug Administration’s (FDA) Arthritis Advisory Committee last month unanimously supported Amgen’s drug candidate ABP 501 as a biosimilar to Abbvie’s Humira (adalimumab). Amgen is seeking to ... Read more

July 22, 2016July 22, 2016

App Enables iPhone to Monitor Rheumatoid Arthritis Study Participants

News

Global pharmaceutical and healthcare products company GlaxoSmithKline (GSK) has launched the “Patient Rheumatoid Arthritis Data from the Real World” (PARADE) clinical study, using Apple iPhones to monitor activity and vital ... Read more

July 15, 2016July 18, 2016

FDA Arthritis Advisory Committee Hears Perspectives on Biosimilar GP2015

News

The U.S. Food and Drug Administration (FDA) held Arthritis Advisory Committee Meetings, July 11-12 in Maryland, and discussed Biologics License Applications (BLA) approvals, including a submission for GP2015, Sandoz‘s proposed biosimilar product to Amgen’s drug ... Read more

June 9, 2016June 9, 2016

#EULAR2016: Corrona Delivers Novel Research Evidence on Rheumatoid Arthritis

News

Southborough, Massachusetts-based Corrona LLC, independent specialists in the compilation of real-world evidence and consulting on auto-immune disorders, is represented at EULAR 2016 — the Annual European Congress of Rheumatology June 8-11 in ... Read more

May 13, 2016May 13, 2016

myVectra, a Web Portal and Mobile App, Helps RA Patients Track Disease Changes

News

Myriad Genetics, Inc., a personalized medicine subsidiary of Crescendo Bioscience, has launched a new web portal called myVectra for people with rheumatoid arthritis (RA). myVectra users can easily access their Vectra DA test results ... Read more

November 9, 2015November 9, 2015

Potential Rheumatoid Arthritis Vaccine Gets Boost from NIH

News

Vienna, Virginia-based CEL-SCI Corporation, a biopharmaceutical company focused on research and development directed at disease treatments that utilize the immune system’s natural defense processes, announced that its investigational LEAPS rheumatoid ... Read more

July 20, 2015July 20, 2015

Roche Receives FDA Breakthrough Therapy Designation, Initiaties New Study For SSc/RA Therapy ACTEMRA/RoACTEMRA

News, rheumatoid arthritis

Basel, Switzerland based multinational pharma giant Roche has been granted breakthrough therapy designation (BTD) status by the U.S. Food and Drug Administration (FDA) for its ACTEMRA/RoACTEMRA (tocilizumab) drugs for treatment ... Read more

May 18, 2015May 18, 2015

Arthritis Power First Ever Patient-Led, Patient-Centered Arthritis Patient Research Registry

News, rheumatoid arthritis

Upper Nyack, N.Y. based online non-profit organization CreakyJoints, with a support community of more than 80,000 patients and their families in all 50 U.S. states, Canada, Western Europe, South America ... Read more

March 5, 2015March 5, 2015

“Million Man Study” Finds Blocking Inflammation Long-Term Can Cause Collateral Damage

News, rheumatoid arthritis

Inflammation, one of the human body’s responses to trauma or other damaging stimuli, is a symptom largely regarded as something we would rather do without. Although inflammation one of the ... Read more